TEMPEST THERAPEUTICS INC (TPST:NASDAQ)
$0.973 -0.0018 (-0.1847%)
Analysed TEMPEST THERAPEUTICS INC (TPST:NASDAQ) News Sources
Tempest Therapeutics Announces Up To $6 Million Private Placement
23-03-2026
yahoo.com
Tempest Reports Year End 2025 Financial Results and Provides Business Update
30-03-2026
yahoo.com
New Strong Buy Stocks for April 10th
10-04-2026
yahoo.com
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
14-04-2026
yahoo.com
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
22-04-2026
yahoo.com
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
29-04-2026
yahoo.com
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
06-05-2026
yahoo.com
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
14-05-2026
yahoo.com
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
29-05-2026
yahoo.com
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
04-06-2026
yahoo.com
What is the current price of TEMPEST THERAPEUTICS INC (TPST:NASDAQ)?
The current price of TEMPEST THERAPEUTICS INC (TPST:NASDAQ) is $0.973.
TEMPEST THERAPEUTICS INC (TPST:NASDAQ) absolute price change since previous trading day?
The absolute price change of TEMPEST THERAPEUTICS INC (TPST:NASDAQ) since the previous trading day is $-0.0018.
TEMPEST THERAPEUTICS INC (TPST:NASDAQ) percentage price change since previous trading day?
The percentage price change of TEMPEST THERAPEUTICS INC (TPST:NASDAQ) since the previous trading day is -0.1847%.
What is the most recent average sentiment score for TEMPEST THERAPEUTICS INC (TPST:NASDAQ)?
The most recent average sentiment score for TEMPEST THERAPEUTICS INC (TPST:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for TEMPEST THERAPEUTICS INC (TPST:NASDAQ)?
The most recent sentiment for TEMPEST THERAPEUTICS INC (TPST:NASDAQ) is .
SEC-8K** Filing Available For TEMPEST THERAPEUTICS INC (TPST:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.